PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m(2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m(2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7). Patients in complete remission (CR) received a single consolidation cycle containing daunorubicin and intermediate-dose cytarabine (500 mg/m(2) every 12 hours for 6 days). Subsequently, a stem-cell transplantation was planned. The primary end point was survival. RESULTS: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable analysis P = .009). For patients younger than age 46 years, survival was 43.3% and 51.9%, respectively (P = .009; multivariable analysis P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, respectively (P = .91). CR rates were 72.0% and 78.7%, respectively (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03). Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with secondary AML benefitted from HD cytarabine. CONCLUSION: HD cytarabine produces higher remission and survival rates than SD cytarabine, especially in patients younger than age 46 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT00004128.

High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial / Willemze, R; Suciu, S; Meloni, G; Labar, B; Marie, Jp; Halkes, Cj; Muus, P; Mistrik, M; Amadori, S; Specchia, G; Fabbiano, F; Nobile, F; Sborgia, M; Camera, A; Selleslag, Dl; Lefrère, F Sr; Magro, D; Sica, S; Cantore, N; Beksac, M; Berneman, Z; Thomas, X; Melillo, L; Guimaraes, Je; Leoni, P; Luppi, M; Mitra, Me; Bron, D; Fillet, G; Marijt, Ew; Venditti, A; Hagemeijer, A; Mancini, M; Jansen, J; Cilloni, D; Meert, L; Fazi, P; Vignetti, M; Trisolini, Sm; Mandelli, F; de Witte, T. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:3(2014), pp. 219-228. [10.1200/JCO.2013.51.8571]

High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial

Meloni G;Amadori S;Sica S;Melillo L;Mancini M;Fazi P;Vignetti M;Mandelli F;
2014

Abstract

PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m(2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m(2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7). Patients in complete remission (CR) received a single consolidation cycle containing daunorubicin and intermediate-dose cytarabine (500 mg/m(2) every 12 hours for 6 days). Subsequently, a stem-cell transplantation was planned. The primary end point was survival. RESULTS: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable analysis P = .009). For patients younger than age 46 years, survival was 43.3% and 51.9%, respectively (P = .009; multivariable analysis P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, respectively (P = .91). CR rates were 72.0% and 78.7%, respectively (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03). Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with secondary AML benefitted from HD cytarabine. CONCLUSION: HD cytarabine produces higher remission and survival rates than SD cytarabine, especially in patients younger than age 46 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT00004128.
Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Risk Assessment; Risk Factors; Treatment Outcome; Cancer Research; Oncology; Medicine (all)
01 Pubblicazione su rivista::01a Articolo in rivista
High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial / Willemze, R; Suciu, S; Meloni, G; Labar, B; Marie, Jp; Halkes, Cj; Muus, P; Mistrik, M; Amadori, S; Specchia, G; Fabbiano, F; Nobile, F; Sborgia, M; Camera, A; Selleslag, Dl; Lefrère, F Sr; Magro, D; Sica, S; Cantore, N; Beksac, M; Berneman, Z; Thomas, X; Melillo, L; Guimaraes, Je; Leoni, P; Luppi, M; Mitra, Me; Bron, D; Fillet, G; Marijt, Ew; Venditti, A; Hagemeijer, A; Mancini, M; Jansen, J; Cilloni, D; Meert, L; Fazi, P; Vignetti, M; Trisolini, Sm; Mandelli, F; de Witte, T. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:3(2014), pp. 219-228. [10.1200/JCO.2013.51.8571]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1189530
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 124
  • ???jsp.display-item.citation.isi??? 114
social impact